|Bid||30.35 x 100|
|Ask||31.30 x 1100|
|Day's range||30.69 - 31.45|
|52-week range||29.39 - 45.87|
|PE ratio (TTM)||25.30|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Dividend & yield||0.00 (0.00%)|
|1y target est||40.67|
In a filing to the U.S. Patent Trial and Appeal Board, the Saint Regis Mohawk Tribe asked that Mylan's case seeking to invalidate Allergan's patents on dry-eye medicine Restasis be thrown out on the grounds that the board has no jurisdiction over the tribe. The move was expected after Allergan announced on Sept. 8 that it had transferred Restasis patents to the tribe in order to protect them from administrative challenges.
Everyone knows high prescription drug prices are a problem, but except for pharma stockholders, few people may realize that price cuts are rippling through the generic side of the industry.
Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.